Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(100.0%)
2Total
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04516993Phase 2Completed

CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II

Role: collaborator

NCT06078995Unknown

Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China

Role: collaborator

NCT04681651Phase 2Completed

Normobaric Hyperoxia Combined With Endovascular Treatment in Acute Ischemic Stroke (OPENS-2)

Role: collaborator

NCT03719820Unknown

Stroke Imaging Package Study of Intracranial Atherosclerosis ( SIPS-ICAS )

Role: collaborator

All 4 trials loaded